Microbio Co., Ltd. (TPEX:4128)

Market Cap	12.29B
Revenue (ttm)	1.86B
Net Income (ttm)	-1.03B
Shares Out	588.17M
EPS (ttm)	-1.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	895,013
Average Volume	2,168,406
Open	21.20
Previous Close	20.90
Day's Range	20.55 - 21.25
52-Week Range	17.90 - 35.65
Beta	0.59
RSI	59.60
Earnings Date	Mar 10, 2026

About Microbio

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Mic...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2000
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4128

Financial Performance

In 2024, Microbio's revenue was 1.72 billion, an increase of 8.26% compared to the previous year's 1.59 billion. Losses were -1.10 billion, -6.70% less than in 2023.